TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
WisdomTree India Earnings Fund ( (EPI) ) has provided an announcement.
ESSA Pharma Inc. has announced a cash distribution of US$80 million to its shareholders, following a court order authorizing a reduction in the capital of its common shares. This distribution is part of the company’s winding-up process and precedes a special meeting to approve a transaction with XenoTherapeutics, Inc., where Xeno will acquire all outstanding common shares. Shareholders are estimated to receive approximately US$1.91 per share, excluding contingent value rights payments. This move marks a significant shift in ESSA’s operations, as it transitions from its previous focus on prostate cancer therapies.
Spark’s Take on EPI Stock
According to Spark, TipRanks’ AI Analyst, EPI is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPI stock, click here.
More about WisdomTree India Earnings Fund
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 944,527
Current Market Cap: $3.02B
For an in-depth examination of EPI stock, go to TipRanks’ Overview page.